
浏览全部资源
扫码关注微信
1.湖南中医药大学,长沙 410208;
2.湖南省中医药研究院 附属医院,长沙 410006
胡琦,博士,讲师,从事恶性肿瘤的中医药防治研究,E-mail:151708440@qq.com
朱克俭,博士生导师,研究员,从事内科疑难杂症的辨证方法学研究,E-mail:zkjo0731@263.net
收稿日期:2018-11-09,
网络出版日期:2019-03-04,
纸质出版日期:2019-11-20
移动端阅览
胡琦, 朱定耀, 谭小宁, 等. 臭牡丹含药血清通过PI3K/Akt信号通路对肝癌细胞的影响[J]. 中国实验方剂学杂志, 2019,25(22):28-33.
Qi HU, Ding-yao ZHU, Xiao-ning TAN, et al. Effect of Drug-containing Serum of Clerodendrum bungei on Liver Cancer Cells Through PI3K/Akt Signaling Pathway[J]. Chinese journal of experimental traditional medical formulae, 2019, 25(22): 28-33.
胡琦, 朱定耀, 谭小宁, 等. 臭牡丹含药血清通过PI3K/Akt信号通路对肝癌细胞的影响[J]. 中国实验方剂学杂志, 2019,25(22):28-33. DOI: 10.13422/j.cnki.syfjx.20191222.
Qi HU, Ding-yao ZHU, Xiao-ning TAN, et al. Effect of Drug-containing Serum of Clerodendrum bungei on Liver Cancer Cells Through PI3K/Akt Signaling Pathway[J]. Chinese journal of experimental traditional medical formulae, 2019, 25(22): 28-33. DOI: 10.13422/j.cnki.syfjx.20191222.
目的:
2
从磷脂酰肌醇3-激酶(PI3K)/丝氨酸苏氨酸蛋白激酶(Akt)信号通路角度探讨臭牡丹含药血清对肝癌MHCC97-H细胞的影响及可能的机制。
方法:
2
臭牡丹15%含药血清作用于MHCC97-H细胞,细胞增殖/毒性法(CCK-8)观察臭牡丹含药血清对细胞增殖的影响,以筛选最佳作用时间和浓度;Annexin V-FITC/碘化丙啶(PI)双染法检测细胞凋亡;蛋白免疫印迹法(Western blot)检测臭牡丹含药血清作用于细胞72 h后对PI3K/Akt信号通路中关键蛋白中第10号染色体缺失的磷酸酶及张力蛋白同源的基因(PTEN),磷酸化Akt(p-Akt)和磷脂酰肌醇3-激酶(PI3K)蛋白表达的影响;实时荧光定量聚合酶链式反应(Real-time PCR)检测臭牡丹含药血清作用于细胞72 h后对核转录因子-
κ
B(NF-
κ
B)和肿瘤坏死因子-
α
(TNF-
α
)mRNA表达的影响。
结果:
2
CCK-8结果显示,与空白组比较,臭牡丹含药血清对肿瘤细胞的增殖抑制作用呈剂量和时间依赖性。其中高剂量组抑制作用最为明显,在24,48,72 h的最大抑制率分别达到28%,32%,43%;流式细胞术结果显示,与空白组比较,随着臭牡丹含药血清浓度的增加,细胞的生长均受不同程度抑制,细胞的凋亡比例亦相应增加,72 h干预组抑制作用显著(
P
<
0.01),臭牡丹含药血清组各时间段最大凋亡率达19.48%,19.72%(
P
<
0.05);Western blot结果显示,与空白组比较,臭牡丹含药血清干预下各组PTEN表达量均升高(
P
<
0.05),PI3K,p-Akt蛋白表达均减少(
P
<
0.05);Real-time PCR结果显示,与空白组比较,臭牡丹含药血清可以下调NF-
κ
B mRNA表达,上调TNF-
α
mRNA的表达(
P
<
0.05)。
结论:
2
臭牡丹含药血清可以有效抑制MHCC97-H肝癌细胞增殖并促进其凋亡,可能与PI3K/Akt信号通路并影响其关键因子有关。
Objective:
2
To investigate the effect of
Clerodendrum bungei
-containing serum on liver cancer MHCC97-H cells and its possible mechanism from the perspective of phosphatidylinositol 3-kinase(PI3K)/protein kinase (Akt) signaling pathway.
Method:
2
The medicinal serum of 15%
C
.
bungei
was used to treat MHCC97-H cells. The effect of serum containing
C
.
bungei
on cell proliferation was observed by cell counting kit-8(CCK-8) method
in order to select the best time and concentration. The apoptosis was detected by Annexin V-FITC/PI double staining method. Western blot was used to detect the posphatase and tensin homologous gene deleted from chromosome 10 in key proteins (PTEN)
phosphoprotein kinase B (p-Akt) and phosphatidylinositol 3-kinase (PI3K)-related protein expression of PI3K/Akt signaling pathway. Real-time PCR was used to detect
C
.
bungei
-containing serum on cells for 72 h after activation of nuclear factor-activated B cell kappa light chain(NF-
κ
B) and tumor necrosis factor-
α
(TNF-
α
) mRNA expression.
Result:
2
The results of CCK-8 showed an inhibitory effect of the
C
.
bungei
-containing serum on the proliferation of tumor cells in a dose and time-dependent manner. Among them
the high-dose group had the most obvious inhibitory effect
and the maximum inhibition rates at 24
48
72 h were 28%
32%
and 43%
respectively. The results of flow cytometry showed that with the increase of drug-containing serum concentration
the cell growth was observed. The inhibition rate of cells was increased to different degrees
and the inhibition effect was significantly increased in the 72 h intervention group (
P
<
0.01). The maximum apoptosis rate of the
C
.
bungei
-containing serum group was 19.48% and 19.72%
compared with the blank group. The difference was significant (
P
<
0.05). The results of Western blot showed that the expression of PTEN in different groups increased with different concentrations of
C
.
bungei
-containing serum (
P
<
0.05)
and the expressions of PI3K and p-Akt decreased (
P
<
0.05). Real-time PCR results showed that the
C
.
bungei
-containing serum could down-regulate the expression of NF-
κ
B and up-regulate the expression of TNF-
α
mRNA (
P
<
0.05).
Conclusion:
2
The medicinal serum of
C
.
bungei
can effectively inhibit the proliferation of MHCC97-H hepatoma cells and promote its apoptosis
which may be related to the PI3K/Akt signaling pathway and its key factors.
SU T S , LU H Z , CHENG T , et al . Long-term survival analysis in combined transarterial embolization and stereotactic body radiation therapy versus stereotactic body radiation monotherapy for unresectable Hepatocellular Carcinoma>5 cm [J]. Bmc Cancer , 2016 , 16 ( 1 ): 834 - 835 .
Barrett M , Nathan H , Vankayala H , et al . Recurrence of hepatocellular carcinoma at surgical incision site: case series and review of literature [J]. Ann R Coll Surg Engl , 2017 , 99 ( 6 ): 77 - 119 .
刘珍 , 邓天好 , 程华初 , 等 . 原发性肝癌临床治疗新进展 [J]. 湖南中医杂志 , 2018 , 34 ( 7 ): 207 - 210 .
何立丽 , 吕文良 , 孙桂芝 . 中药提取物抗原发性肝癌的研究进展 [J]. 中华中医药杂志 , 2014 , 29 ( 4 ): 1175 - 1178 .
欧阳剑虹 , 朱克俭 . 欧阳锜 [J]. 湖南中医杂志 , 1997 ( 6 ): 2 - 3 .
朱克俭 , 张亚利 , 欧阳剑虹 , 等 . 保肺饮预防肺癌的临床流行病学研究 [J]. 中国中医药科技 , 1997 ( 6 ): 332 - 333 .
陈思勤 , 朱克俭 , 程晓燕 , 等 . 臭牡丹化学成分及其药理作用研究进展 [J]. 湖南中医杂志 , 2012 , 28 ( 2 ): 141 - 142 .
余娜 , 朱克俭 , 马思静 , 等 . 臭牡丹总黄酮对A549细胞增殖迁移侵袭力及Wnt通路相关蛋白的影响 [J]. 世界中医药 , 2018 , 13 ( 4 ): 978-983,987 .
余娜 , 朱克俭 , 马思静 , 等 . 臭牡丹总黄酮通过调控Wnt/β-catenin通路影响A549细胞上皮间质转化研究 [J]. 中草药 , 2018 , 49 ( 3 ): 663 - 670 .
陈思勤 , 朱克俭 , 李勇敏 , 等 . 臭牡丹总黄酮抑制小鼠Lewis肺癌实体瘤及其与p53、bcl-2、bax表达相关性研究 [J]. 世界中医药 , 2016 , 11 ( 6 ): 946 - 949 .
胡琦 , 朱克俭 , 谭小宁 , 等 . 臭牡丹总黄酮对人肝癌HepG2细胞增殖作用的实验研究 [J]. 湖南中医杂志 , 2015 , 31 ( 2 ): 166 - 168 .
胡琦 , 谭小宁 , 余娜 , 等 . 臭牡丹总黄酮介导Wnt/β-catenin信号转导诱导人肝癌细胞HepG2的凋亡 [J]. 世界中医药 , 2016 , 11 ( 2 ): 954 - 957 .
Spangle J M , Roberts T M , ZHAO J J . The emerging role of PI3K/Akt-mediated epigenetic regulation in cancer [J]. Biochim Biophys Acta , 2017 , 1868 ( 1 ): 123 - 131 .
GAI J Q , SHENG X , QIN J M , et al . The effect and mechanism of bufalin on regulating hepatocellular carcinoma cell invasion and metastasis via Wnt/β-catenin signaling pathway [J]. Int J Oncol , 2016 , 48 ( 1 ): 338 - 348 .
张蕊 , 彭芳 . 中药影响肝癌细胞信号转导通路的研究进展 [J]. 医学综述 , 2017 , 23 ( 5 ): 931 - 934 .
周红林 , 刘建新 , 周俐 , 等 . 臭牡丹提取物抗炎镇痛抗过敏作用的实验研究 [J]. 中国新药杂志 , 2006 ( 23 ): 2027 - 2029 .
诸佳瑜 , 陈闯 , 欧杰 , 等 . 中医辩证治疗原发性肝癌的研究进展 [J]. 当代医药论丛 , 2017 , 15 ( 10 ): 32 - 34 .
马星 , 夏伟 . 中药抗肝癌细胞增殖和诱导细胞凋亡的信号通路研究进展 [J]. 上海中医药杂志 , 2018 , 52 ( 8 ): 98 - 101 .
CHO D C . Targeting the PI3K Akt mTOR pathway in malignancy: rationale and clinical outlook [J]. Bio Drugs , 2014 , 28 ( 4 ): 373 - 381 .
Babichev Y , Kabaroff L , Datti A , et al . PI3K/Akt/ MtoR inhibition in combination with doxorubicin is an effective therapy for leiomyosarcoma [J]. J Transl Med , 2016 , 14 ( 1 ): 67 - 71 .
WAN X W , JIANG M , CAI H F , et al . The alteration of PTEN tumor suppressor expression and its association with the histopathological features of human primary hepatocellular carcinoma . [J]. J Cancer Res Clin Oncol , 2003 , 129 ( 2 ): 100 - 106 .
黎金华 , 吴万垠 , 杨小兵 . 扶正抗癌方通过PTEN/PI3K/Bad通路调控肺癌A549细胞增殖与凋亡 [J]. 中国实验方剂学杂志 , 2017 , 23 ( 21 ): 98 - 103 .
Riquelme I , Tapia O , Leal P , et al . miR-101-2, miR- 125b-2 and miR-451a act as potential tumor suppressors in gastric cancer through regulation of the PI3K/Akt/mTOR pathway [J]. Cell Oncol: Dordr , 2016 , 39 ( 1 ): 23 - 33 .
李平 , 胡建燃 , 铁军 . 柴胡总皂苷通过Akt/NF-κB信号通路抑制胃癌细胞MGC80-3的增殖和迁移 [J]. 中国细胞生物学学报 , 2018 , 40 ( 10 ): 1727 - 1735 .
Spangle J M , Roberts T M , ZHAO J J . The emerging role of PI3K/Akt-mediated epigenetic regulation in cancer [J]. Biochim Biophys Acta , 2017 , 1868 ( 1 ): 123 - 31 .
邹乐兰 , 刘红宁 , 吕红 , 等 . 左归丸抗乳腺癌转移及其作用机制 [J]. 中国实验方剂学杂志 , 2017 , 23 ( 23 ): 85 - 90 .
陶静怡 , 李敏 , 胡利江 , 等 . 玉屏风颗粒联合西药对反复上呼吸道感染肺气虚证患者免疫功能及血清IL-6、TNF-α水平的影响 [J]. 浙江中西医结合杂志 , 2018 , 28 ( 4 ): 263-266,270 .
0
浏览量
15
下载量
1
CSCD
关联资源
相关文章
相关作者
相关机构
京公网安备11010802024621